Guy Melamed, the CFO and COO of $VRNS, sold 51,889 shares of the company on 08-01-2025 for an estimated $2,859,083. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.9% of their shares of this class of stock. Following this trade, they now own 470,602 shares of this class of $VRNS stock.
$VRNS Insider Trading Activity
$VRNS insiders have traded $VRNS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRNS stock by insiders over the last 6 months:
- GUY MELAMED (CFO and COO) sold 51,889 shares for an estimated $2,859,083
- DEN BOSCH FRED VAN has made 0 purchases and 2 sales selling 9,000 shares for an estimated $465,240.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VRNS Hedge Fund Activity
We have seen 162 institutional investors add shares of $VRNS stock to their portfolio, and 179 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 1,373,919 shares (+134.2%) to their portfolio in Q1 2025, for an estimated $55,575,023
- VOYA INVESTMENT MANAGEMENT LLC added 1,152,687 shares (+98.6%) to their portfolio in Q1 2025, for an estimated $46,626,189
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 1,084,651 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,874,132
- THRIVENT FINANCIAL FOR LUTHERANS removed 1,065,635 shares (-40.7%) from their portfolio in Q1 2025, for an estimated $43,104,935
- POLAR CAPITAL HOLDINGS PLC removed 1,003,524 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $40,592,545
- TWO SIGMA ADVISERS, LP added 893,200 shares (+64.7%) to their portfolio in Q1 2025, for an estimated $36,129,940
- GOLDMAN SACHS GROUP INC added 848,408 shares (+26.2%) to their portfolio in Q1 2025, for an estimated $34,318,103
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VRNS Analyst Ratings
Wall Street analysts have issued reports on $VRNS in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 07/30/2025
- UBS issued a "Buy" rating on 07/30/2025
- Barclays issued a "Overweight" rating on 07/30/2025
- Susquehanna issued a "Positive" rating on 07/30/2025
- Baird issued a "Outperform" rating on 07/30/2025
- Wedbush issued a "Outperform" rating on 07/30/2025
- Needham issued a "Buy" rating on 07/30/2025
To track analyst ratings and price targets for $VRNS, check out Quiver Quantitative's $VRNS forecast page.
$VRNS Price Targets
Multiple analysts have issued price targets for $VRNS recently. We have seen 14 analysts offer price targets for $VRNS in the last 6 months, with a median target of $63.5.
Here are some recent targets:
- Daniel Ives from Wedbush set a target price of $65.0 on 07/30/2025
- Shyam Patil from Susquehanna set a target price of $65.0 on 07/30/2025
- Mike Cikos from Needham set a target price of $70.0 on 07/30/2025
- Shrenik Kothari from Baird set a target price of $63.0 on 07/30/2025
- Matthew Hedberg from RBC Capital set a target price of $64.0 on 07/30/2025
- Rudy Kessinger from DA Davidson set a target price of $50.0 on 07/30/2025
- Saket Kalia from Barclays set a target price of $62.0 on 07/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
